Pliant Therapeutics(US:PLRX)2026-03-11 20:31Clinical Trials - PLN-101095 Phase 1 trial data showed four responders, including one confirmed complete response and three partial responses, out of 10 secondary ICI refractory patients[3] - The accelerated development plan for PLN-101095 includes a Phase 1b indication expansion trial, with first patient enrollment anticipated in Q2 2026[3] - PLN-101095 Phase 1 data accepted for presentation at the AACR Annual Meeting 2026, highlighting the ongoing commitment to advancing clinical research[3] Financial Performance - Net loss for Q4 2025 was $23.6 million, down from $49.7 million in the prior-year quarter, mainly due to the discontinuation of BEACON-IPF and reduced personnel costs[9] - Total operating expenses for Q4 2025 were $23.6 million, compared to $53.3 million in the prior-year quarter[13] - Research and development expenses decreased to $15.6 million in Q4 2025 from $38.8 million in the prior-year quarter, primarily due to the discontinuation of BEACON-IPF[9] - General and administrative expenses decreased to $8.0 million in Q4 2025 from $14.5 million in the prior-year quarter, attributed to lower personnel-related costs from workforce restructuring[9] Assets and Liabilities - As of December 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $192.4 million, expected to fund operations into the second half of 2028[9] - The company’s total assets as of December 31, 2025, were $225.2 million, down from $396.9 million in the prior year[15] - The accumulated deficit increased to $859.4 million as of December 31, 2025, compared to $710.1 million in the prior year[15]